Investment Analysts’ Recent Ratings Updates for Regeneron Pharmaceuticals (REGN)

Several brokerages have updated their recommendations and price targets on shares of Regeneron Pharmaceuticals (NASDAQ: REGN) in the last few weeks:

  • 2/9/2018 – Regeneron Pharmaceuticals was given a new $430.00 price target on by analysts at SunTrust Banks, Inc.. They now have a “hold” rating on the stock.
  • 2/9/2018 – Regeneron Pharmaceuticals had its price target raised by analysts at Morgan Stanley from $401.00 to $415.00. They now have an “equal weight” rating on the stock.
  • 2/9/2018 – Regeneron Pharmaceuticals had its price target lowered by analysts at Leerink Swann from $568.00 to $502.00. They now have an “outperform” rating on the stock.
  • 2/9/2018 – Regeneron Pharmaceuticals was upgraded by analysts at Robert W. Baird from a “neutral” rating to an “outperform” rating. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 2/9/2018 – Regeneron Pharmaceuticals was given a new $530.00 price target on by analysts at Guggenheim. They now have a “buy” rating on the stock.
  • 2/8/2018 – Regeneron Pharmaceuticals had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $380.00 price target on the stock.
  • 2/8/2018 – Regeneron Pharmaceuticals was downgraded by analysts at BTIG Research from a “buy” rating to a “neutral” rating. They now have a $480.00 price target on the stock.
  • 2/8/2018 – Regeneron Pharmaceuticals had its price target raised by analysts at BMO Capital Markets from $398.00 to $444.00. They now have a “market perform” rating on the stock.
  • 2/7/2018 – Regeneron Pharmaceuticals was given a new $440.00 price target on by analysts at Credit Suisse Group AG. They now have a “buy” rating on the stock.
  • 2/7/2018 – Regeneron Pharmaceuticals had its “hold” rating reaffirmed by analysts at Cowen Inc. They now have a $450.00 price target on the stock.
  • 2/7/2018 – Regeneron Pharmaceuticals had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $522.00 price target on the stock. They wrote, “We are encouraged by better US Dupixent growth, but recognize that the pediatric atopic dermatitis market will be the core growth driver, with approval expected around 2021. Also, while we understand that REGN and investors are focusing more on Dupixent’s growth than EYLEA’s, the lack of EYLEA guidance going forward is concerning. REGN cannot give guidance on Dupixent since Sanofi books the revenues, and EYLEA is still expected to be the core revenue driver for REGN.””
  • 2/5/2018 – Regeneron Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Regeneron’s Eylea continues to perform well. Dupixent launch in the United States for moderate-to-severe atopic dermatitis is progressing well. Moreover, the company is also looking to expand Dupixent’s label in uncontrolled asthma. The approval of new drugs like Kevzara and Dupixent provides a significant boost. However, sales of Praluent have failed to impress. With Eylea accounting for the majority of revenues at Regeneron, Regeneron relies heavily on the drug for growth. In the United States., the company is witnessing increased competitor discounts and rebates. Sub-par performance of the product will hurt the stock as Eylea is Regeneron’s key growth driver. Moreover, Eylea combination studies with nesvacumab disappointed in phase II and hence the study will not be advanced into phase III. Shares have underperformed the industry in the last twelve months. Estimates have increased ahead of Q4 results.”
  • 2/2/2018 – Regeneron Pharmaceuticals had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $421.00 price target on the stock.
  • 1/26/2018 – Regeneron Pharmaceuticals was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 1/24/2018 – Regeneron Pharmaceuticals had its price target raised by analysts at JPMorgan Chase & Co. from $455.00 to $457.00. They now have a “neutral” rating on the stock.
  • 1/9/2018 – Regeneron Pharmaceuticals had its “neutral” rating reaffirmed by analysts at Citigroup Inc. They now have a $388.00 price target on the stock, up previously from $380.00.
  • 12/28/2017 – Regeneron Pharmaceuticals had its price target lowered by analysts at Argus from $540.00 to $470.00. They now have a “buy” rating on the stock.
  • 12/14/2017 – Regeneron Pharmaceuticals had its “hold” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $430.00 price target on the stock.

Shares of Regeneron Pharmaceuticals Inc (REGN) opened at $340.00 on Monday. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.82 and a quick ratio of 3.18. Regeneron Pharmaceuticals Inc has a 1 year low of $314.99 and a 1 year high of $543.55. The company has a market cap of $36,140.33, a PE ratio of 32.95, a price-to-earnings-growth ratio of 1.27 and a beta of 1.47.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 EPS for the quarter, topping the consensus estimate of $4.18 by $1.05. Regeneron Pharmaceuticals had a net margin of 20.41% and a return on equity of 28.48%. The firm had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.50 billion. During the same period in the previous year, the business earned $3.04 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 28.9% compared to the same quarter last year. equities analysts anticipate that Regeneron Pharmaceuticals Inc will post 14.13 EPS for the current year.

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply